[Federal Register Volume 83, Number 223 (Monday, November 19, 2018)]
[Notices]
[Page 58265]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25194]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Sickle Cell Anemia Treatment Through RIOK3 Inhibition

    Available for licensing and commercial development are methods for 
the treatment of beta-globinapathies such as sickle cell disease and 
beta-thalassemia by inhibiting the expression and/or activity of RIOK3 
in erythroid cells such as primary erythroid progenitor cell or a CD34+ 
erythroid cells. RIOK3 inhibitors contemplated within the scope of the 
invention can be antibodies, siRNAs, microRNAs, antisense 
oligonucleotides or small molecules like Midostaurin, Axitinib, 
Bosutinib, or Ruxolitinib.

Potential Commercial Applications:

 Sickle cell disease
 beta thalassemia

Development Stage:

 Early stage
    Inventors: Bjorg Gudmundsdottir, Laxminath Tumburu, John Tisdale 
(all of NHLBI)
    Intellectual Property: HHS Reference No. E-200-2018; U.S 
Provisional Patent Application 62/756,497 filed November 6, 2018.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: November 7, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-25194 Filed 11-16-18; 8:45 am]
 BILLING CODE 4140-01-P